INJECTION INDEXWeight management, clearly.
The online care edition
October 2026
The plan index · October 2026

Semaglutide Injection Offers

Identify the product and compare the care and payment pathways.

Read this firstSources checked October 7, 2026

Semaglutide evidence belongs to the studied product and regimen. Offer prices do not establish equivalent preparations.

Semaglutide 2.4 mg
14.9%

Mean percentage reduction in the randomized treatment group.

Placebo
2.4%

Both groups also received lifestyle intervention.

Semaglutide is an ingredient name, not one universal online product. Wegovy is an approved branded medicine, while some providers advertise compounded preparations using semaglutide. These pathways differ in product status and should not be merged simply because a headline uses the same ingredient.

The entries below cover a published compounded offer, clinical membership models, and official branded information. A clinician should assess the actual product and the reader’s medical history. Use the review to learn what to confirm, then discuss the prescription before enrollment.

02

SuperHealthy Rx

Compounded GLP-1 care

Publisher score 9.7/10

The offer

Semaglutide $85/month; tirzepatide $135/month advertised

A current-source review of SuperHealthy Rx GLP-1 care: a written plan that can be compared fairly, billing questions and evidence limits.

Open the complete review →
Advertised priceSemaglutide $85/month; tirzepatide $135/month advertisedVisit provider ↗
What to compare

Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.

03

Likeness Rx

Compounded semaglutide or tirzepatide

Publisher score 9.5/10

The offer

Semaglutide $948/year ($79/mo equivalent) or $139 month-to-month; tirzepatide terms differ

Likeness Rx offers compounded semaglutide and tirzepatide with explicit term pricing. Its lowest advertised monthly equivalents are $79 and $129 on annual prepaid terms; month-to-month options cost more.

Open the complete review →
Advertised priceFrom $79/mo equivalentVisit provider ↗
What to compare

Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.

04

Noom Med

Plan-specific billing
The offer

Introductory and ongoing rates differ

A program with several treatment and billing tracks; identify your exact plan before comparing the headline.

Open the complete review →
Advertised pricePlan variesVisit provider ↗
What to compare

Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.

05

Ro

Introductory membership
The offer

Membership and medication billed separately

Ro separates the cost of its care membership from the prescription cost.

Open the complete review →
Advertised price$39 startVisit provider ↗
What to compare

Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.

06

Mochi Health

Membership only
The offer

Ongoing membership; medication costs extra

Mochi’s recurring membership and medicine charges need to be read together.

Open the complete review →
Advertised price$79/moVisit provider ↗
What to compare

Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.

07

Wegovy

Branded medicine
The offer

Manufacturer medicine information; not a clinic

Wegovy is a branded semaglutide medicine record, not a clinic; its current forms, indications and savings terms must remain distinct from a provider’s package.

Open the complete review →
Advertised priceOffer variesVisit provider ↗
What to compare

Confirm the exact preparation, renewal, supplied amount, pharmacy, and clinical follow-up for the chosen order.

The details, visualized

Semaglutide evidence anchor: STEP 1

Mean reduction from baseline body weight (%)

  1. Semaglutide 2.4 mg14.9%

    Mean percentage reduction in the randomized treatment group.

  2. Placebo2.4%

    Both groups also received lifestyle intervention.

Group averages, not individual predictions. Doses identify trial arms, not dosing advice. These data do not establish outcomes for compounded preparations. Bars start at zero.

View the printable chart imageSemaglutide evidence anchor: STEP 1. The same values and context are available in the data table above.
Research note 01

Use the trial as context, not a provider score

STEP 1 gives an evidence anchor for a specific once-weekly semaglutide regimen in adults without diabetes. It does not measure the service quality of the online providers in this list or validate an unspecified compounded vial. The medicine’s route, formulation and approved indication must remain attached to any research claim.

For the purchasing comparison, ask whether the quote describes branded access or a compounded preparation, what the clinician’s rationale is, and what instructions accompany the supplied product. A shared ingredient name is not enough to reuse another provider’s concentration or administration instructions.

Before you decide

Questions worth answering

Does the order on this page identify the best treatment for me?

No. It is a publisher-arranged comparison of selected public offers. The chart explains the specific purchase or evidence question; a licensed clinician must assess the actual treatment.

What should I verify for this comparison?

Semaglutide evidence belongs to the studied product and regimen. Offer prices do not establish equivalent preparations. Ask for the selected written quote and the product-specific clinical explanation before making a purchase.

Evidence behind this page

Sources & chart notes

Checked October 7, 2026. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
Semaglutide Injection Offers — keep the exact product identity and its complete label together.

An approved product has its own information

Use the official Wegovy information for its indications and safety discussion. Clinical results are not promises for an individual, and they do not establish the performance of an unspecified compounded preparation. Read the Wegovy product profile for the source links.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
An approved product has its own information — keep the exact product identity and its complete label together.

A compounded offer needs an individual rationale

Ask why an approved medicine cannot meet your needs and which pharmacy supplies the preparation. Confirm the formulation and written directions. The product-status guide explains why a compounded product is not an FDA-approved generic.

Membership is not always the medicine price

A low care fee can leave the pharmacy expense separate. Match the product, supplied quantity, and normal renewal with the membership charges. The invoice worksheet turns those different figures into a useful comparison.

Explore the review directory and full cost table to compare the details of another offer.

Research record

Documents used

Source register refreshed October 7, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.

  1. FDA: Concerns about unapproved GLP-1 drugs ↗
  2. NIDDK: Prescription medicines for weight management ↗
  3. Wegovy: Official product information ↗
  4. Zepbound: Official product information ↗